Vutrisiran ATTR Cm denied as experimental or investigational by Cigna?

Cigna's specific coverage criteria for vutrisiran attr cm are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna May Deny Vutrisiran (ATTR-CM) as Experimental — and Why You Can Appeal

Vutrisiran (Amvuttra) received FDA approval for transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM). An "experimental" or "investigational" denial from Cigna typically means the plan's medical policy has not yet been updated to reflect the FDA-approval indication, or that Cigna has applied an older policy version that predates the ATTR-CM approval. This is one of the most clearly reversible denial types because FDA approval is a matter of public record.

## Why This Denial Is Appealable

An FDA-approved drug prescribed for its approved indication cannot lawfully be classified as experimental under most plan definitions of that term. Under ACA §2719, you have the right to an internal appeal and then an independent external review. Under ERISA §503 (for employer-sponsored plans), a full-and-fair review is required. External review — conducted by a reviewer with no connection to Cigna — is particularly powerful for experimental denials, because independent reviewers evaluate whether the plan's characterization of the therapy is consistent with current scientific and regulatory consensus. The external-review window is typically available for approximately four months after a final internal denial, and expedited review is available when your health is at risk.

## What to Gather

• FDA approval documentation: Print the current FDA label for vutrisiran directly from the FDA website and attach it as Exhibit A. Highlight the approved indication that matches your diagnosis.
• Diagnosis confirmation: Cardiologist chart notes, imaging, biopsy or nuclear scan results confirming ATTR-CM.
• Prescriber medical-necessity letter: A letter from your cardiologist stating that vutrisiran is prescribed for its FDA-approved indication and is consistent with current clinical practice guidelines from the ACC or AHA.
• Cigna's policy definition: Request Cigna's written definition of "experimental" or "investigational" and its medical policy for vutrisiran. Compare that definition against the FDA approval status.
• Clinical society position statements: Ask your cardiologist to reference any ACC/AHA guideline statements or consensus documents supporting vutrisiran use in ATTR-CM.

## Criteria-Mapping Structure

Address Cigna's experimental determination directly:

> Cigna's stated basis for experimental classification: [paste verbatim from denial] > Rebuttal: [FDA approval date, indication, and chart confirmation that your use matches the approved indication]

## Timeline

File your internal appeal immediately. Confirm the exact deadline in your denial letter. Given the progressive nature of ATTR-CM, request expedited review in writing. After a final internal denial, file for independent external review promptly.